Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
NEWARK, Calif., Jan. 27, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will hold an Analyst and Investor Day in New York City on Wednesday, March 23, 2016 from 9:00 a.m. ET – 11:30 a.m. ET (6:00 a.m. PT – 8:30 a.m. PT). Depomed’s President and Chief Executive Officer Jim Schoeneck and members of the company's management team will be joined by Joseph V. Pergolizzi, Jr., MD, an Adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine in Baltimore, Maryland and an internationally recognized leader in the area of pain medicine and management. The event will provide a business overview as well as a review of the marketed and development-stage product pipeline.
Space is limited and attendance is by invitation only. The presentations, as well as the question and answer session, will be webcast and will be accessible via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days. Additional event details will be available closer to the event date.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
